15 investors back Tokyo healthtech startups in 2026. Japan is the world's most aged society. Beyond Next and UTEC fund health science here, with pharma CVCs in the mix.
Japan is the world's most aged society. Nearly 30% of people are over 65 here.
That drives huge demand for healthtech. Eldercare and prevention come first here.
Most money is biotech and pharma CVCs. Takeda and Terumo both invest in it.
Cheques run seed to growth here. Pharma CVCs lead the bigger rounds.
Cross-border biotech funds now reach in too. They co-invest with the pharma arms.
Healthtech investors run long, hard diligence. Ellty keeps every file ready in one data room.
| Type | Check size | Sector focus | Website | |
|---|---|---|---|---|
| Beyond Next Ventures | Deep-tech / health VC | US$0.7M-$13M | Biotech, medtech, digital health | beyondnextventures.com |
| UTEC | University life-science VC | US$0.5M-$10M | Biotech, life science, health | ut-ec.co.jp |
| Coral Capital | Seed VC (digital health) | US$0.2M-$3.3M | Digital health, healthcare SaaS | coralcap.co |
| ANRI | Seed VC (life sciences) | US$0.3M-$3M | Life sciences, digital health | anri.vc |
| Real Tech Holdings | Deep-tech (med/bio) VC | US$0.5M-$5M | Medtech, biotech, healthcare | untrod.inc |
| Fast Track Initiative | Healthcare / life-science VC | US$1M-$5M | Biotech, diagnostics, digital health | fasttrackinitiative.com |
| SBI Investment | Corporate / institutional VC | US$1M-$15M | Healthcare, biotech, broad | sbinvestment.co.jp |
| Globis Capital Partners | Multi-stage VC | US$3M-$15M | Digital health, tech | globiscapital.co.jp |
| Global Brain | Multi-stage VC + CVC | US$1M-$15M+ | Digital health, broad tech | globalbrains.com |
| Takeda Ventures | Corporate VC (pharma) | US$3M-$20M+ | Biotech, therapeutics | takeda.com |
| Terumo Ventures | Corporate VC (medtech) | US$1M-$5M | Medtech, digital health | terumo.com |
| Z Venture Capital | Corporate VC (LY Corp) | US$1M-$10M | Digital health, AI healthcare | zvc.vc |
| Catalys Pacific | Cross-border biotech VC | US$5M-$20M+ | Biotech, therapeutics | catalyspacific.com |
| Remiges Ventures | Cross-border biotech VC | US$1.5M-$5M+ | Biotech, drug discovery | remigesventures.com |
| World Innovation Lab (WiL) | Cross-border VC | US$5M-$30M+ | Digital health, telemedicine | wilab.com |
Keep your healthtech data room ready
Healthtech funds run long diligence on your trials and data. Ellty logs every view so you know who is serious.
Start free 14-day trialWhat a healthtech investor backs
A healthtech investor backs outcomes and approvals. They want proof your science holds up.
Tokyo funds split bio and digital health. Most run a formal venture capital process.
They study your trials, data, and reimbursement. AI now speeds much of this research.
They look for a clear payer on the other side. Strong science with no buyer rarely wins.
Ellty gives each fund one trackable link to your room. You see who studied your data before the call.
Ubie has seen growing acknowledgment of the impact we provide to patients, providers, and the healthcare system, supported by funding from established healthcare companies.
15 Tokyo healthtech investors
1. Beyond Next Ventures
Beyond Next has Japan's deepest health and biotech bench.
Recent Activity: Backs biotech and medtech from a Rs 25.7B fund
LinkedIn: Beyond Next Ventures LinkedIn
Sector Focus: Biotech, medtech, digital health
Stage Focus: Seed, Series A
Check Size: US$0.7M-$13M
Location: Tokyo
Website: beyondnextventures.com
2. UTEC
UTEC backs life science and biotech from UTokyo's labs.
Recent Activity: Runs a strong healthcare pillar from a US$1B+ base
LinkedIn: UTEC LinkedIn
Sector Focus: Biotech, life science, health
Stage Focus: Seed to growth
Check Size: US$0.5M-$10M
Location: Tokyo
Website: ut-ec.co.jp
3. Coral Capital
Coral is a Tokyo seed fund active in digital health.
Recent Activity: Backs digital health and healthcare SaaS at seed
LinkedIn: Coral Capital LinkedIn
Sector Focus: Digital health, healthcare SaaS
Stage Focus: Seed, Series A
Check Size: US$0.2M-$3.3M
Location: Tokyo
Website: coralcap.co
4. ANRI
ANRI backs life-sciences and digital-health founders early.
Recent Activity: A Tokyo seed fund with a life-sciences sleeve
LinkedIn: ANRI LinkedIn
Sector Focus: Life sciences, digital health
Stage Focus: Seed, Series A
Check Size: US$0.3M-$3M
Location: Tokyo
Website: anri.vc
5. Real Tech Holdings
Real Tech backs medtech and biotech from research.
Recent Activity: Puts 30%+ of its portfolio into health and biotech
Sector Focus: Medtech, biotech, healthcare
Stage Focus: Seed to growth
Check Size: US$0.5M-$5M
Location: Tokyo
Website: untrod.inc
6. Fast Track Initiative
FTI is a dedicated Japanese life-science fund.
Recent Activity: Closed a US$130M fourth fund in 2025
LinkedIn: Fast Track Initiative LinkedIn
Sector Focus: Biotech, diagnostics, digital health
Stage Focus: Seed, early
Check Size: US$1M-$5M
Location: Tokyo (+ US)
Website: fasttrackinitiative.com
Share one link with every health fund
Ellty shows when Beyond Next or UTEC opens your deck. Follow up with each fund at the right time.
Start free 14-day trial7. SBI Investment
SBI is one of Japan's largest investors, active in health.
Recent Activity: Backs healthcare and biotech across a broad book
LinkedIn: SBI Investment LinkedIn
Sector Focus: Healthcare, biotech, broad
Stage Focus: Early to growth
Check Size: US$1M-$15M
Location: Tokyo
Website: sbinvestment.co.jp
8. Globis Capital Partners
Globis is a top Tokyo VC active in digital health.
Recent Activity: A heavyweight backer of Japanese tech and health
LinkedIn: Globis Capital Partners LinkedIn
Sector Focus: Digital health, tech
Stage Focus: Series A to growth
Check Size: US$3M-$15M
Location: Tokyo
Website: globiscapital.co.jp
9. Global Brain
Global Brain backs digital health among many sectors.
Recent Activity: A large Tokyo independent with a US$2.3B+ base
LinkedIn: Global Brain LinkedIn
Sector Focus: Digital health, broad tech
Stage Focus: Seed to growth
Check Size: US$1M-$15M+
Location: Tokyo
Website: globalbrains.com
10. Takeda Ventures
Takeda Ventures is the CVC of Japan's largest pharma.
Recent Activity: Backs biotech and therapeutics from Takeda R&D sites
LinkedIn: Takeda Ventures LinkedIn
Sector Focus: Biotech, therapeutics
Stage Focus: Early to growth
Check Size: US$3M-$20M+
Location: US (Takeda's CVC)
Website: takeda.com
11. Terumo Ventures
Terumo Ventures is the CVC of medtech giant Terumo.
Recent Activity: Launched a US$75M medtech fund in 2024
Sector Focus: Medtech, digital health
Stage Focus: Early-stage
Check Size: US$1M-$5M
Location: US (Terumo's CVC)
Website: terumo.com
12. Z Venture Capital
ZVC backs data and AI in healthcare from Tokyo.
Recent Activity: Backs AI healthcare from a Rs 30B fund
Sector Focus: Digital health, AI healthcare
Stage Focus: Seed to growth
Check Size: US$1M-$10M
Location: Tokyo
Website: zvc.vc
13. Catalys Pacific
Catalys is a US-Japan biotech company-creation fund.
Recent Activity: Backed by Eisai, Chugai, and Takeda as LPs
LinkedIn: Catalys Pacific LinkedIn
Sector Focus: Biotech, therapeutics
Stage Focus: Early to growth
Check Size: US$5M-$20M+
Location: Tokyo / Seattle
Website: catalyspacific.com
14. Remiges Ventures
Remiges builds biotech on Japanese-academia science.
Recent Activity: Runs a US$95M fund with Taiho and BMS as LPs
LinkedIn: Remiges Ventures LinkedIn
Sector Focus: Biotech, drug discovery
Stage Focus: Seed to early
Check Size: US$1.5M-$5M+
Location: Cambridge / Tokyo
Website: remigesventures.com
15. World Innovation Lab (WiL)
WiL backed Tokyo telemedicine company MICIN.
Recent Activity: An investor in telemedicine firm MICIN
LinkedIn: World Innovation Lab LinkedIn
Sector Focus: Digital health, telemedicine
Stage Focus: Growth
Check Size: US$5M-$30M+
Location: Tokyo / Palo Alto (backed MICIN)
Website: wilab.com
Aging drives Japan healthtech
Nearly 30% of Japan is over 65 now. That pushes healthtech up the agenda.
Health spending tops Y46 trillion a year. Eldercare and prevention lead demand.
Elderly demand never slows here. Funds back care that scales cheaply.
Caregivers are scarce and costly. That pulls money into care tech.
A clinical demo still needs real outcomes. Use Ellty features to share your data.
Read our due diligence for investors guide. Ellty logs who opened each file and when.
Digital therapeutics lead the way
Ubie built an AI symptom checker from Tokyo. CureApp won the first DTx approvals.
MICIN runs telemedicine across Japan now. Reimbursement is still the hardest step.
A reimbursement code unlocks scale. Funds prize a clear payer path.
A first approval de-risks the rest. One win opens the next door.
Patient and trial data is highly sensitive. Store it in one secure virtual data room.
Ellty controls who can open each sensitive file. You see exactly who studied your data and when.
From trial to funded health startup
A trial result still needs a path to market. Each round wants a bigger proof point than before.
Health rounds run longer and need approvals. Investors dig deep into the hard science.
A paid pilot beats a free trial. Funds want a clinic that renews.
A named hospital partner adds weight. One site can anchor the round.
Run a clean due diligence file from day one. Get ready before the questions start.
Learn how to prepare for due diligence early. Ellty tracks who opened what file and when.
How to pitch a Tokyo healthtech investor
Lead with outcomes and clear approvals.
- 1.Lead with outcomes and clear approvals.Healthtech funds back proven results, so open with the data and the regulatory path.
- 2.Show a clear path to reimbursement.Approval alone won't pay the bills, so map who pays and how much.
- 3.Name your first paying clinic or hospital.Funds want real demand, so show who already uses and renews your product.
- 4.Share one Ellty link to your whole data room.Skip scattered email attachments and track who opens which files in real time.
- 5.Follow up the same day a fund digs in.Ellty flags the moment they open your data, so you reach out while interest is high.
How Ellty helps you land a healthtech investor in Tokyo
You've shortlisted your Tokyo healthtech funds already. Set up a data room before the first call.
- 1.Upload your trial data, metrics, and deck.Set access per fund or per partner.
- 2.Share one trackable link with each fund.Each fund gets its own tracked link.
- 3.Watch opens and follow up at the right time.Use Ellty analytics to time each nudge.
Tokyo healthtech investor questions
- Beyond Next and UTEC back health science. Takeda and Terumo run pharma CVCs.
- Cheques run US$0.3M to US$20M in 2026 here. Biotech rounds run larger than that.
- It is the world's most aged society. That drives huge healthtech demand.
- No, it stays smaller than the US. Most money is biotech and pharma CVCs.
- Real outcomes and clear approvals. A path to reimbursement too.
- Before your very first investor call. Track who opens your deck and data.
